Business
Gntbm's Self-Developed Anti-Cancer New Drug Gntbm-38 Has Obtained Ind Approval From The U.S. FDA For Phase I Clinical Trials
Gntbm's Self-Developed Anti-Cancer New Drug Gntbm-38 Has Obtained Ind Approval From The U.S. FDA For Phase I Clinical Trials
About this update from Great Novel Therapeutics Biotech & Medicals Corp.
GNT Biotech & Medicals Corp TPEX:7427:GNTBM'S SELF-DEVELOPED ANTI-CANCER NEW DRUG GNTBM-38 HAS OBTAINED IND APPROVAL FROM THE U.S. FDA FOR PHASE I CLINICAL TRIALSGNT BIOTECH & MEDICALS CORP - GNTBM TO ADVANCE GNTBM-38 INTO MULTI-NATIONAL CLINICAL TRIALS IN U.S., CHINA, TAIWAN
View stock analysis, news, and events for Great Novel Therapeutics Biotech & Medicals Corp.